These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24432609)

  • 1. [Immunotherapy for infectious diseases: challenges and prospects].
    Karaulov AV; Kaliuzhin OV
    Ter Arkh; 2013; 85(11):100-8. PubMed ID: 24432609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of pattern-recognizing receptors in anti-infectious immunity].
    Tukhvatulin AI; Shcherbinin DN; Logunov DIu; Shmarov MM; Naroditskiĭ BS
    Vestn Ross Akad Med Nauk; 2011; (10):47-54. PubMed ID: 22168039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulators as adjuvants for vaccines and antimicrobial therapy.
    Nicholls EF; Madera L; Hancock RE
    Ann N Y Acad Sci; 2010 Dec; 1213():46-61. PubMed ID: 20946578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of biologic response modifiers in infectious disease.
    Masihi KN; Schäfer H
    Infect Dis Clin North Am; 2011 Dec; 25(4):723-31. PubMed ID: 22054752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural product derived immune-regulatory agents.
    Talmadge JE
    Int Immunopharmacol; 2016 Aug; 37():5-15. PubMed ID: 26968760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine immunomodulation for the treatment of infectious diseases: lessons from primary immunodeficiencies.
    Vinh DC
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1069-100. PubMed ID: 24881679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers.
    Buchwald UK; Pirofski L
    Curr Pharm Des; 2003; 9(12):945-68. PubMed ID: 12678861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory approaches for prevention and treatment of infectious diseases.
    Nijnik A
    Curr Opin Microbiol; 2013 Oct; 16(5):590-5. PubMed ID: 23870826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fish immunity and parasite infections: from innate immunity to immunoprophylactic prospects.
    Alvarez-Pellitero P
    Vet Immunol Immunopathol; 2008 Dec; 126(3-4):171-98. PubMed ID: 18783835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors.
    Romagne F
    Drug Discov Today; 2007 Jan; 12(1-2):80-7. PubMed ID: 17198976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The basics and advances of immunomodulators and antigen presentation: a key to development of potent memory response against pathogens.
    Garai P; Gogoi M; Gopal G; Radhakrishnan Y; Nandakumar KS; Chakravortty D
    Expert Opin Biol Ther; 2014 Oct; 14(10):1383-97. PubMed ID: 24897303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular NOD-like receptors in innate immunity, infection and disease.
    Franchi L; Park JH; Shaw MH; Marina-Garcia N; Chen G; Kim YG; Núñez G
    Cell Microbiol; 2008 Jan; 10(1):1-8. PubMed ID: 17944960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate immunity: toll-like receptors and some more. A brief history, basic organization and relevance for the human newborn.
    Fleer A; Krediet TG
    Neonatology; 2007; 92(3):145-57. PubMed ID: 17476116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for Using Muramyl Peptides - Modulators of Innate Immunity of Bacterial Origin - in Medicine.
    Guryanova SV; Khaitov RM
    Front Immunol; 2021; 12():607178. PubMed ID: 33959120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New prospects for immunotherapy at diagnosis of type 1 diabetes.
    Pozzilli P; Leslie RD
    Diabetes Metab Res Rev; 2009 May; 25(4):299-301. PubMed ID: 19405079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using antimicrobial host defense peptides as anti-infective and immunomodulatory agents.
    Kruse T; Kristensen HH
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):887-95. PubMed ID: 19053901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients.
    Page AV; Liles WC
    Curr Opin Organ Transplant; 2008 Dec; 13(6):575-80. PubMed ID: 19060545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy and vaccination after transplant: the present, the future.
    Emery VC; Einsele H; Atabani S; Haque T
    Infect Dis Clin North Am; 2010 Jun; 24(2):515-29. PubMed ID: 20466281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases.
    Tlaskalová-Hogenová H; Stepánková R; Hudcovic T; Tucková L; Cukrowska B; Lodinová-Zádníková R; Kozáková H; Rossmann P; Bártová J; Sokol D; Funda DP; Borovská D; Reháková Z; Sinkora J; Hofman J; Drastich P; Kokesová A
    Immunol Lett; 2004 May; 93(2-3):97-108. PubMed ID: 15158604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.